UMUC3/Human CTR-RAMP1(AMY1) Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0041D | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
AMY1 (CTR-RAMP1) is a heterodimeric G protein-coupled receptor complex composed of the calcitonin receptor and receptor activity-modifying protein 1. It is primarily distributed in the central nervous system (e.g., hypothalamus, nucleus accumbens), pancreas, and stomach. Its core function is to act as a high-affinity receptor for amylin and CGRP, mediating potent control over energy homeostasis via signaling pathways such as cAMP inhibition. This includes inducing central satiety, delaying gastric emptying, and modulating glucagon secretion to control postprandial glucose. Thus, AMY1 is a key therapeutic target for type 2 diabetes and obesity, with its agonist (e.g., pramlintide) already in clinical use.
Screeningbio’s UMUC3/Human CTR-RAMP1(AMY1) cell line overexpress CALCR & RAMP1 and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | CALCR & RAMP1 |
Accession Number | NM_001742 & NM_005856 |
Parental Line | UMUC3 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
AMY1 (CTR-RAMP1) is a heterodimeric G protein-coupled receptor complex composed of the calcitonin receptor and receptor activity-modifying protein 1.
It is primarily distributed in the central nervous system (e.g., hypothalamus, nucleus accumbens), pancreas, and stomach. Its core function is to act as a high-affinity receptor for amylin and CGRP, mediating potent control over energy homeostasis via signaling pathways such as cAMP inhibition.
This includes inducing central satiety, delaying gastric emptying, and modulating glucagon secretion to control postprandial glucose. Thus, AMY1 is a key therapeutic target for type 2 diabetes and obesity, with its agonist (e.g., pramlintide) already in clinical use.